Dr. Balar highlights promising evidence on the potential benefits of the use of immunotherapy in the advanced bladder cancer setting.
Arjun V. Balar, MD
Advertisement
Articles by Arjun V. Balar, MD
Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Ruxolitinib Tablets for Hematologic Malignancies
2
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
3
Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer
4
Precision Medicine and the “Slow Death” of Transplant in Lymphoma
5